3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Taste Disorders
1
Parasomnias
1
Pain
1
Olfaction Disorders
1
Neoplasms
1
Nausea
1
Marijuana Abuse
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Cancer Pain
1
Breast Neoplasms
1
Anxiety Disorders
1
Anorexia
1
Interventions
Dexamethasone
12
Palonosetron
11
Aprepitant
11
Ondansetron
8
Olanzapine
5
Calcium Dobesilate
4
netupitant
2
fosaprepitant
2
Tropisetron
2
Radiotherapy
2
Fluorouracil
2
yangzheng xiaoji
1
rolapitant
1
ramosetron
1
niraparib
1
netupitant, palosentron drug combination
1
nabiximols
1
isatuximab
1
ginger extract
1
dolasetron
1
casopitant
1
Yoga
1
Therapeutics
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Radiation
1
Paclitaxel
1
Oxaliplatin
1
Octreotide
1
Midazolam
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Nausea
×
Dronabinol
×
Clear all
NCT03948074
2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2
Completed
91 enrolled